Cellular reprogramming of somatic cells into induced pluripotent stem cells (iPSC) opens up new avenues for basic research and regenerative medicine. However, the low efficiency of the procedure remains a major limitation. To identify iPSC, many studies to date relied on the activation of pluripotency-associated transcription factors. Such strategies are either retrospective or depend on geneti...

Pluripotent genomes are folded in a topological hierarchy that reorganizes during differentiation. The extent to which chromatin architecture is reconfigured during somatic cell reprogramming is poorly understood. Here we integrate fine-resolution architecture maps with epigenetic marks and gene expression in embryonic stem cells (ESCs), neural progenitor cells (NPCs), and NPC-derived induced p...

The recent breakthrough in reprogramming somatic cells has invigorated the prospect that disease mechanisms that underpin various human diseases particularly the neurodegenerative disorders could be unravelled by using the disease-specific pluripotent stem cells. A number of studies have demonstrated that such disease-specific induced pluripotent stem cell (iPSC) could be generated relatively e...

Generation of induced pluripotent stem cells (iPSC) is considered one of the major biological discoveries of the 21st century. IPSC were originally obtained in 2006-2007 by Japanese scientists first from mouse fibroblasts, and later from adult human fibroblasts [1,2]. IPSC have provided a unique platform for studying pathogenesis of different diseases and opened the door to their clinical appli...

The discovery that somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) raised the exciting possibility of modeling diseases with patient-specific cells. Marchetto et al. (2010) now use iPSC technology to generate, characterize, and treat an in vitro model for the autism spectrum disorder Rett syndrome.

Objective: This study attempted to graft neural precursor cells (NPCs) differentiated from mouse induced pluripotent stem cells (iPSc) with gelatin sponge-electrospun Poly (lactic-co-glycolic acid)-Polyethylene glycol (PLGA/ PEG) nanofibers into transected rat spinal cords and to investigate whether the tissue engineering scaffolds could promote motor functional recovery. Methods: iPSc were dif...

Induced pluripotent stem cells (iPSCs) were first described in 2006 and have since emerged as a promising cell source for clinical applications. The rapid progression in iPSC technology is still ongoing and directed toward increasing the efficacy of iPSC production and reducing the immunogenic and tumorigenic potential of these cells. Enormous efforts have been made to apply iPSC-based technolo...

Left Ventricular Noncompaction Cardiomyopathy (LVNC) is characterized by excessive trabeculation of the left ventricle. To date, mutations in more than 40 genes have been associated with LVNC, however exact mechanisms underlying disease remain unknown. Here, we describe an induced pluripotent stem cell (iPSC) line (UALGi001-A) from a LVNC patient (LVNC-iPSC) that does not present most commonly ...

Pluripotent stem cells are exhibited similarly in the morphology, gene expression, growth properties, and epigenetic modification with embryonic stem cells (ESCs). However, it is still controversial that the pluripotency of induced pluripotent stem cell (iPSC) is much inferior to ESC, and the differentiation capacity of iPSC and ESC can also be separated by transcriptome and epigenetics. miRNAs...

Increasingly, human induced pluripotent stem cells (iPSC) and their associated genetic and clinical information are being used in a wide range of applications, with large biobanks being established to support and increase their scientific use. The new European General Data Protection Regulations, which comes into effect in 2018, will have implications for biobanks that generate, store and allow...